Hikari Power Ltd Makes New Investment in Zoetis Inc. $ZTS

Hikari Power Ltd bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 8,790 shares of the company’s stock, valued at approximately $632,000. Zoetis makes up about 0.1% of Hikari Power Ltd’s investment portfolio, making the stock its 27th largest position.

Several other large investors have also recently made changes to their positions in the business. Brighton Jones LLC raised its stake in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC grew its stake in shares of Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the last quarter. Intech Investment Management LLC increased its holdings in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after acquiring an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after acquiring an additional 1,422 shares in the last quarter. Finally, Glenview Trust co raised its position in shares of Zoetis by 11.8% in the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $73.64 on Monday. Zoetis Inc. has a fifty-two week low of $71.45 and a fifty-two week high of $160.48. The business has a 50-day simple moving average of $76.30 and a two-hundred day simple moving average of $98.84. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The firm has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a price-to-earnings-growth ratio of 1.28 and a beta of 0.73.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts expect that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. Zoetis’s dividend payout ratio is 34.93%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Barclays dropped their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Morgan Stanley set a $85.00 price target on shares of Zoetis in a report on Friday, August 7th. Finally, Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.